Technology
Health
Biotechnology

Seattle Genetics

$73.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-0.16%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SGEN and other stocks, options, ETFs, and crypto commission-free!

About

Seattle Genetics, Inc. Common Stock, also called Seattle Genetics, is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Read More Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Employees
1,302
Headquarters
Bothell, Washington
Founded
1997
Market Cap
11.86B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
918.30K
High Today
$74.41
Low Today
$71.12
Open Price
$73.67
Volume
318.28K
52 Week High
$84.37
52 Week Low
$47.75

Collections

Technology
Health
Biotechnology
Cancer Prevention
US
North America

News

Associated PressMar 21

Global Hodgkin’s Lymphoma Drugs Market Outlook, 2019 to 2023 - Bristol-Myers Squibb Company, Merck & Co, Ono Pharmaceutical Co, Pfizer, and Seattle Genetics are Dominating - ResearchAndMarkets.com

This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. Global Hodgkin’s Lymphoma Drugs Market Outlook, 2019 to 2023 - Bristol-Myers Squibb Company, Merck & Co, Ono Pharmaceutical Co, Pfizer, and Seattle Genetics are Dominating - ResearchAndMarkets.com This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. DUBLIN--(BUSINESS WIRE)--Mar 2...

95
Yahoo FinanceMar 9

Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. A month has gone by since the last earnings report for Seattle Genetics (SGEN). Shares have lost about 6.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Seattle Genetics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick loo...

85
Simply Wall StMar 7

If You Had Bought Seattle Genetics Shares Three Years Ago You’d Have Made 113%

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more than 100%. To wit, the Seattle Genetics, Inc. (NASDAQ:SGEN) share price has flown 113% in the last three years. That sort of return is as solid as granite. It’s also good to see the share price up 12% over the last quarter. See our latest analysis for Seattle Genetics Seattle Genetics isn’t currently profitable, ...

96

Earnings

-$0.75
-$0.39
-$0.02
$0.34
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.